FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compounds of formula I or their pharmaceutically acceptable salts. Compounds by invention possess properties of JAK2 kinase inhibitors. In formula I 
R1 represents phenyl, optionally substituted with 1-3 R6; R2 represents phenyl, optionally substituted with 1-2 R7; R3, R4 and R5 independently represent H. values of the rest of radicals are presented in invention formula. Invention also relates to particular compounds, structural formulae of which are presented in invention formula.
EFFECT: novel compounds, possessing properties of JAK2 kinase inhibitor have been obtained.
11 cl, 2 tbl, 312 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | 2009 |
|
RU2561104C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| CONDENSED TRIAZOLAMINES AS P2X7 MODULATORS | 2010 |
|
RU2533122C2 |
| TRIAZOLIUM SALT AS RAR1 INHIBITORS, PREPARING THEM AND USING AS DRUG PREPARATION | 2009 |
|
RU2494100C2 |
| TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO-[3,4-C]-1,2,4-TRIAZOLO- -[4,3-A]-PYRIDINES, METHOD OF INHIBITION OF ACTIVITY OF PHOSPHODIESTERASE TYPE IV AND METHOD OF INHIBITION OF TUMOR-SPECIFIC NECROSIS FACTOR PRODUCING | 1996 |
|
RU2161158C2 |
| ALLOSTERIC MODULATORS OF METABOLIC GLUTAMATE RECEPTORS | 2004 |
|
RU2360902C2 |
| ENZYMES INHIBITION | 2013 |
|
RU2638537C2 |
| COMPOUNDS AND COMPOSITIONS AS ITPKb INHIBITORS | 2007 |
|
RU2425826C2 |
| COMPOUNDS AND COMPOSITIONS AS CANNABINOID RECEPTOR 1 INHIBITORS | 2005 |
|
RU2431635C2 |
| PHENOXYMETHYL DERIVATIVES | 2016 |
|
RU2746481C1 |
